Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19

Maximilian F Konig; Alfred Hj Kim; Marc H Scheetz; Elizabeth R Graef; Jean W Liew; Julia Simard; Pedro M Machado; Milena Gianfrancesco; Jinoos Yazdany; Daman Langguth; Philip C Robinson; COVID-19 Global Rheumatology Alliance

doi:10.1136/annrheumdis-2020-217690

Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19

Ann Rheum Dis. 2020 Oct;79(10):1386-1388. doi: 10.1136/annrheumdis-2020-217690. Epub 2020 May 7.

Authors

Maximilian F Konig¹, Alfred Hj Kim^{2

3

4}, Marc H Scheetz^{5

6}, Elizabeth R Graef⁷, Jean W Liew⁸, Julia Simard⁹, Pedro M Machado^{10

11

12}, Milena Gianfrancesco¹³, Jinoos Yazdany¹³, Daman Langguth¹⁴, Philip C Robinson¹⁵; COVID-19 Global Rheumatology Alliance

Affiliations

¹ Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA konig@jhmi.edu philip.robinson@uq.edu.au.
² Division of Rheumatology, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.
³ Division of Immunobiology, Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.
⁴ Andrew M. and Jane M. Bursky Center of Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, Missouri, USA.
⁵ Departments of Pharmacy Practice and Pharmacology; Pharmacometrics Center of Excellence, Midwestern University, Chicago College of Pharmacy, and College of Graduate Studies, Downers Grove, Illinois, USA.
⁶ Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois, USA.
⁷ Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
⁸ Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington, USA.
⁹ Department of Epidemiology & Population Health; Department of Medicine, Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, California, USA.
¹⁰ Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK.
¹¹ Department of Rheumatology & Queen Square Centre for Neuromuscular Diseases, University College London Hospitals NHS Foundation Trust, London, UK.
¹² Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK.
¹³ Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
¹⁴ Department of Immunology, Sullivan Nicolaides Pathology, Brisbane, Queensland, Australia.
¹⁵ The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia konig@jhmi.edu philip.robinson@uq.edu.au.

No abstract available

Keywords: epidemiology; hydroxychloroquine; lupus erythematosus, systemic; pharmacokinetics.

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Adult
Aged
Antirheumatic Agents / blood
Antirheumatic Agents / therapeutic use*
Betacoronavirus
COVID-19
Case-Control Studies
Coronavirus Infections / epidemiology*
Coronavirus Infections / physiopathology
Coronavirus Infections / therapy
Dose-Response Relationship, Drug
Extracorporeal Membrane Oxygenation / statistics & numerical data
Female
Hospitalization / statistics & numerical data
Humans
Hydroxychloroquine / blood
Hydroxychloroquine / therapeutic use*
Lupus Erythematosus, Systemic / drug therapy*
Lupus Erythematosus, Systemic / epidemiology
Male
Middle Aged
Oxygen Inhalation Therapy
Pandemics
Pneumonia, Viral / epidemiology*
Pneumonia, Viral / physiopathology
Pneumonia, Viral / therapy
Respiration, Artificial / statistics & numerical data
SARS-CoV-2
Severity of Illness Index

Substances

Antirheumatic Agents
Hydroxychloroquine

Publication types

MeSH terms

Substances

Grants and funding